Summary
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates the RAS mechanism, shifting competition to tolerability and dose intensity, where ERAS-0015 shows potential differentiation. ERAS-0015 demonstrates strong tolerability, no dose-limiting toxicities, and high dose intensity, supporting its case for durable efficacy in key indications.
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point
Erasca, Inc. offers exposure to the RAS/MAPK oncology space at a fraction of Revolution Medicines' valuation, with a $6.7bn market cap versus RVMD's $38.5bn. ERAS-0015's Phase 1 data show promising efficacy and safety, with higher response rates and lower severe adverse events compared to Revolution's daraxonrasib. Patent infringement allegations from Revolution and a patient death initially pressured ERAS, but recent data, a Merck collaboration, and a $632.5m raise have driven a sharp recovery.
Erasca, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 465 | $2,494.71 | $6,835.5 | $4,340.79 | 174% |
| NA Nizar Araji National Bank Of Canada /FI/ | 46 | $643.08 | $684.02 | $40.94 | 6.37% |
| BG Bart Gancher Intech Investment Management LLC | 44,284 | $85,511.73 | $658,503.08 | $572,991.35 | 670.07% |
| KT Kevin Tang Tang Capital Management LLC | 200,000 | $254,000 | $2.94M | $2.69M | 1,057.48% |
| CD Charlie Durham Sterling Capital Management LLC | 703 | $1,532.55 | $10,334.1 | $8,801.55 | 574.31% |
Erasca, Inc. (ERAS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Erasca, Inc. ever had a stock split?
Erasca, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jonathan E. Lim CEO | NASDAQ (NGS) Exchange | 29479A108 CUSIP |
| US Country | 103 Employees | - Last Dividend | - Last Split | 16 Jul 2021 IPO Date |
Overview
Erasca, Inc. is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies designed to combat RAS/MAPK pathway-driven cancers. With a robust portfolio of product candidates at various stages of development, the company aims to address the unmet needs of patients suffering from these challenging diseases. Erasca, Inc. was founded in 2018 and has its headquarters in San Diego, California. The company has established partnerships with Novartis, Katmai Pharmaceuticals, Inc., and NiKang Therapeutics, Inc. to further its mission in developing effective cancer treatments. These strategic alliances enhance Erasca's capabilities in manufacturing, usage, and commercialization of its pioneering oncology therapies.
Products and Services
- Naporafenib
As the company's lead product, naporafenib is currently in a Phase 1b trial targeting patients with RAS Q16X solid tumors. Additionally, Erasca, Inc. is preparing to launch a pivotal Phase 3 trial for individuals diagnosed with NRASm melanoma. This advancement stems from a licensing agreement with Novartis aimed at the development and commercialization of naporafenib, highlighting its potential as a significant therapeutic option.
- ERAS-007
ERAS-007 is an oral inhibitor of ERK1/2 in development for treating non-small cell lung cancer, colorectal cancer, and advanced gastrointestinal malignancies. By targeting these critical components of the RAS/MAPK pathway, ERAS-007 stands as an important contributor to the company's diverse oncology pipeline, showcasing its commitment to addressing a range of cancer types with precision treatments.
- ERAS-601
As an oral SHP2 inhibitor, ERAS-601 is designed for patients with advanced or metastatic solid tumors. This development is part of an agreement with NiKang Therapeutics, Inc., emphasizing Erasca's focus on partnerships to advance its pipeline of cancer therapies. The compound ERAS-601 exemplifies the company's strategy of targeting the RAS/MAPK pathway through innovative avenues.
- ERAS-801
In collaboration with Katmai Pharmaceuticals, Inc., ERAS-801 is a central nervous system-penetrant EGFR inhibitor currently undergoing Phase 1 clinical trials. This treatment is directed at patients with recurrent glioblastoma multiforme, a notably aggressive and difficult-to-treat brain tumor. The development of ERAS-801 reflects Erasca's dedication to pushing the boundaries of precision oncology and offering hope to patients facing grim prognoses.
Contact Information
